ACRUX LIMITED — Capital/Financing Update 2009

Jun 3, 2009

==> picture [115 x 730] intentionally omitted <==

----- Start of picture text ----- 04.06.09----- End of picture text -----

==> picture [114 x 66] intentionally omitted <==

ACRUX SIGNS ELLAVIE™ DISTRIBUTION AGREEMENT FOR SOUTH AFRICA

Melbourne, 4 June 2009: Acrux (ASX: ACR) today announced the first marketing and distribution agreement outside the US and Australia for its unique estradiol spray, Ellavie™. Distribution rights for the spray have been granted to a leading South African pharmaceutical company, Aspen Pharmacare (“Aspen’). Aspen will market and promote the product in South Africa.

Under the exclusive distribution agreement, Acrux will receive a signing fee, further fees on achievement of marketing authorisation in South Africa and a distribution fee based on net sales. Aspen is responsible for obtaining the necessary regulatory approvals for the product. The agreement is subject to the approval of the Exchange Control Department of the South African Reserve Bank.

Ellavie™ is currently marketed in the US as Evamist™ and is under evaluation by the regulatory authorities in Australia and Sweden. Aspen Pharmacare Australia was previously appointed as the exclusive distributor for Ellavie™ in Australia and New Zealand.

“We are very pleased to be working with Aspen, given their market position and formidable track record of delivery in the southern African region”, said Acrux CEO Dr Richard Treagus. “We anticipate entering into further agreements for Ellavie™ with distributors in a number of other pharmaceutical markets around the world”.

About Ellavie™

Ellavie™ is a small, hand-held spray, designed to provide an easy and convenient means of delivering a preset dose of estradiol via the skin, in order to reduce symptoms that affect quality of life for many menopausal women. Ellavie™ is placed gently against the skin and an actuator button is pushed, releasing a light spray containing a proprietary formulation of estradiol. The spray is fast drying, non-irritating and invisible after application. Estradiol is released into the blood stream on a sustained basis over 24 hours.

For more information contact:

Dr Richard Treagus, CEO & Managing Director +61 417 520 509 or +61 3 8379 0100

==> picture [92 x 66] intentionally omitted <==

==> picture [360 x 66] intentionally omitted <==

==> picture [16 x 187] intentionally omitted <==

About Acrux - www.acrux.com.au

• Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.

• Fast-drying, invisible sprays or liquids provide a delivery platform with low or no skin irritation, superior cosmetic acceptability and simple, accurate and flexible dosing. The technology platform is covered by broad and welldifferentiated, issued patents.

• Acrux has one product, Evamist™ (brand name Ellavie™ outside the USA) to treat menopause symptoms, marketed by its licensee in the USA and has the following products in clinical development:

  • AXIRON™ to treat testosterone deficiency in men

  • Testosterone MDTS[®] to treat decreased libido in women

  • Nestorone[®] MDTS[®] contraceptive sprays for women

  • An undisclosed companion animal health product

  • Nicotine MDTS[®] for smoking cessation

• Acrux has licensed US rights for Evamist™ to KV Pharmaceutical, US rights for Testosterone MDTS[®] to VIVUS, and distribution rights for Ellavie™ in Southern Africa and AUS/NZ to Aspen Pharmacare. Acrux has also licensed its technology to Eli Lilly and Company for veterinary healthcare products and has an exclusive alliance with Orion Corporation for commercial product supply.

About Aspen - www.aspenpharma.com

Aspen’s holding company, Aspen Pharmacare Holdings Limited (“the Group”), is listed on the Johannesburg Stock Exchange Limited (“JSE”) (JSE code: APN) and has a market capitalisation exceeding AUD 2.9 billion. Aspen is Africa’s largest pharmaceutical manufacturer and is a major supplier of high-quality, affordable pharmaceutical products to both its domestic and export markets. The Group has operations in South Africa, Australia, India, Brazil, Mexico, Venezuela, Kenya, Tanzania, Mauritius and Dubai, covering distribution of products into more than 100 territories worldwide. The Group also has a strong manufacturing base including fifteen manufacturing facilities across eleven sites on three continents.

==> picture [114 x 66] intentionally omitted <==

==> picture [361 x 66] intentionally omitted <==

==> picture [92 x 66] intentionally omitted <==